{"id":68183,"date":"2026-06-15T20:35:03","date_gmt":"2026-06-15T12:35:03","guid":{"rendered":"https:\/\/flcube.com\/?p=68183"},"modified":"2026-06-15T20:35:04","modified_gmt":"2026-06-15T12:35:04","slug":"simcere-pharmaceutical-secures-nmpa-approval-for-sim0689-bispecific-antibody-targeting-pd-1-and-vegf-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68183","title":{"rendered":"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Simcere Pharmaceutical Group (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG: 2096<\/a>)<\/strong> announced that <strong>SIM0689<\/strong>, a novel <strong>bispecific antibody (BsAb)<\/strong> targeting both <strong>programmed death receptor 1 (PD-1)<\/strong> and a <strong>specific epitope of vascular endothelial growth factor (VEGF)<\/strong>, has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>advanced solid tumors<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SIM0689 (bispecific antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>June 15, 2026<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase I clinical trials pending initiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> PD-1\/VEGF bispecific antibody (BsAb)<\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong> Simultaneously relieves tumor immune suppression (via PD-1 blockade) and inhibits angiogenesis (via VEGF targeting)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class bispecific approach combining immune checkpoint inhibition with anti-angiogenic therapy in a single molecule<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Patients with advanced solid tumors across multiple cancer types<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Model System<\/th><th>Key Findings<\/th><\/tr><\/thead><tbody><tr><td><strong>Humanized Mouse Efficacy Models<\/strong><\/td><td>Excellent antitumor effects demonstrated even at low doses<\/td><\/tr><tr><td><strong>Comparative Analysis<\/strong><\/td><td>Overall efficacy significantly superior to similar monospecific or combination molecules<\/td><\/tr><tr><td><strong>Dose Response<\/strong><\/td><td>Potent activity observed across multiple dose levels with favorable therapeutic window<\/td><\/tr><tr><td><strong>Tumor Types Tested<\/strong><\/td><td>Broad activity across various solid tumor models suggesting pan-tumor applicability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The development of <strong>SIM0689<\/strong> represents Simcere&#8217;s strategic focus on <strong>innovative bispecific antibodies<\/strong> that address multiple tumor resistance mechanisms simultaneously. By combining <strong>PD-1 blockade<\/strong> with <strong>VEGF inhibition<\/strong> in a single molecule, SIM0689 aims to overcome limitations of current combination therapies, including complex dosing regimens and increased toxicity profiles.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Solid Tumor Market:<\/strong> China&#8217;s solid tumor therapeutics market exceeds <strong>\u00a550 billion annually<\/strong>, with significant unmet needs in advanced disease settings<\/li>\n\n\n\n<li><strong>PD-1\/VEGF Combinations:<\/strong> Current standard approaches require separate administration of anti-PD-1 and anti-VEGF agents, creating logistical and safety challenges<\/li>\n\n\n\n<li><strong>Bispecific Advantage:<\/strong> Single-molecule approach potentially offers improved pharmacokinetics, reduced immunogenicity, and simplified treatment protocols<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Among the first PD-1\/VEGF bispecific antibodies to enter clinical development in China, positioning Simcere at the forefront of next-generation immuno-oncology<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-strategy-amp-timeline\" class=\"wp-block-heading\">Development Strategy &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Trial Design:<\/strong> Phase I dose-escalation study in multiple solid tumor types<\/li>\n\n\n\n<li><strong>Primary Endpoints:<\/strong> Safety, maximum tolerated dose, and preliminary efficacy signals<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Heavily pre-treated patients with advanced solid tumors refractory to standard therapies<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in Chinese trials could support international development given the universal relevance of PD-1\/VEGF pathways<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061201693_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061201693_c.\"><\/object><a id=\"wp-block-file--media-0490b449-f315-4050-ba23-8694ae7cd8d0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061201693_c.pdf\">2026061201693_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061201693_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0490b449-f315-4050-ba23-8694ae7cd8d0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1099,28,18,271],"class_list":["post-68183","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-2096","tag-multi-specific-antibodies","tag-pd-1-l1","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both programmed death receptor 1 (PD-1) and a specific epitope of vascular endothelial growth factor (VEGF), has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68183\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both programmed death receptor 1 (PD-1) and a specific epitope of vascular endothelial growth factor (VEGF), has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68183\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T12:35:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T12:35:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68183#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68183\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors\",\"datePublished\":\"2026-06-15T12:35:03+00:00\",\"dateModified\":\"2026-06-15T12:35:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68183\"},\"wordCount\":432,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 2096\",\"Multi-specific antibodies\",\"PD-1\\\/L1\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68183#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68183\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68183\",\"name\":\"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-15T12:35:03+00:00\",\"dateModified\":\"2026-06-15T12:35:04+00:00\",\"description\":\"Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both programmed death receptor 1 (PD-1) and a specific epitope of vascular endothelial growth factor (VEGF), has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68183#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68183\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68183#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both programmed death receptor 1 (PD-1) and a specific epitope of vascular endothelial growth factor (VEGF), has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68183","og_locale":"en_US","og_type":"article","og_title":"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors","og_description":"Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both programmed death receptor 1 (PD-1) and a specific epitope of vascular endothelial growth factor (VEGF), has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=68183","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T12:35:03+00:00","article_modified_time":"2026-06-15T12:35:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68183#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68183"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors","datePublished":"2026-06-15T12:35:03+00:00","dateModified":"2026-06-15T12:35:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68183"},"wordCount":432,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 2096","Multi-specific antibodies","PD-1\/L1","Simcere Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68183#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68183","url":"https:\/\/flcube.com\/?p=68183","name":"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-15T12:35:03+00:00","dateModified":"2026-06-15T12:35:04+00:00","description":"Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both programmed death receptor 1 (PD-1) and a specific epitope of vascular endothelial growth factor (VEGF), has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68183#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68183"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68183#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68183"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68183\/revisions"}],"predecessor-version":[{"id":68185,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68183\/revisions\/68185"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}